Nigerian Pharma 9M 2026 Scorecard: May & Baker Wins on Quality, Fidson on Scale, MeCure Carries the Debt
May & Baker had the best-quality nine months of 2026 among Nigeria's four listed drugmakers: its margins expanded, it holds net cash, and at about 9.7x trailing earnings it is the cheapest stock in the group. Fidson is the scale leader, but its profit growth leans heavily on vanishing FX losses and a stretched working-capital cycle. MeCure's operations are strong, but its debt burden absorbs half of operating profit and its share price already assumes success. Neimeth's 9M 2026 numbers could not be verified, and that gap is itself a finding.
At a glance
Ranking on quality of 9M 2026 earnings and valuation: May & Baker > Fidson > MeCure > Neimeth.
May & Baker: gross margin up to about 44.3% from 34.2%, PAT up 76% to N5.89bn, net cash of about N3.91bn, about 9.7x trailing earnings.
Fidson: the scale leader with N112.61bn of revenue, but about 69% of its N5.89bn pre-tax profit increase came from FX losses falling to N104m from N4.16bn.
MeCure: EBIT up 34% and EBIT margin up to about 24.9%, but finance costs of N8.84bn ate about 51% of that EBIT. At about 28x trailing earnings and 9x book, there is little room for error.
Neimeth: still a leveraged turnaround. At H1 2026, finance costs consumed about 80% of operating profit. We could not verify its 9M 2026 numbers before publication.
Table 1: Growth and profitability (9M 2026, N'bn unless stated)
Metric | Fidson | MeCure | May & Baker (Group) | Neimeth (H1 2026*) |
Revenue | 112.61 | 70.24 | 30.97 | 3.66 |
Revenue growth y/y | +21.0% | +17.0% | +4.9% | +26% |
Gross margin | 43.5% (41.1%) | 34.4% (34.0%) | 44.3% (34.2%) | ~49.7% |
Operating (EBIT) margin | 18.9% (18.2%) | 24.9% (21.7%) | 27.3% (17.2%) | ~31% |
Net margin | 10.4% (8.6%) | 8.6% (7.4%) | 19.0% (11.3%) | ~5.7% |
PAT | 11.74 (+47%) | 6.05 (+36%) | 5.89 (+76%) | 0.208 (+2%) |
Opex (S&D + admin) / revenue | 24.8% | 10.1% | 16.7% | n/v |
Q3 revenue growth y/y | +25.3% | +11.6% | +14.1% | n/v |
Q3 PAT growth y/y | +106% | +49% | +132% | n/v |
Neimeth figures are H1 2026 (latest verified). Prior-year figures are in brackets. Margins, opex ratios and Q3 growth rates are TNI Research calculations from reported figures. n/v = not verified.
Table 2: Balance sheet, cash and returns (30 Sep 2026)
Metric | Fidson | MeCure | May & Baker | Neimeth (H1 2026*) |
Finance cost (9M) | 3.73 | 8.84 | 0.37 | 0.91 (H1) |
Interest cover (EBIT/finance cost) | ~5.7x | ~1.98x | ~22.9x | ~1.25x |
Total borrowings | 23.85 | 59.51 | 3.25 | ~9.95 facility (Jan 2026) |
Cash | 10.93 | 4.32 | 7.16 | 1.19 |
Net debt / (net cash) | 12.92 | 55.18 | (3.91) | ~8.8 (indicative) |
Net debt / equity | ~22% | ~224% | net cash | ~3x (indicative) |
Inventory days | ~158 | ~108 | ~154 | n/v |
Receivable days | ~71 | ~69 | ~36 | n/v |
Operating cash flow / PAT | ~2.8x (payables-driven) | ~1.7x (no tax paid) | ~0.9x | n/v |
Capex / revenue | 8.9% | 23.8% | 6.6% | n/v |
Annualised ROE | ~26% | ~33% | ~42% | n/m |
All ratios are TNI Research calculations. Neimeth borrowings are the N9.947bn total debt facility disclosed in its May 2026 rights circular, set against June 2026 cash, so its net debt figure is indicative only.
Table 3: Valuation (end-September 2026 prices)
Metric | Fidson | MeCure | May & Baker | Neimeth |
Share price | N85.00 | N56.20 | N39.20 | ~N7.70 |
Market cap | ~N255bn | ~N224.8bn | ~N67.6bn | ~N34.7bn |
TTM PAT | ~N13.65bn | ~N8.06bn | ~N6.98bn | ~N0.98bn (to June) |
P/E (TTM) | ~18.7x | ~27.9x | ~9.7x | ~35x (indicative) |
P/B | ~4.2x | ~9.1x | ~3.6x | ~12x |
Last dividend / yield | N1.50 / ~1.8% | N0.32 / ~0.6% | N0.50 / ~1.3% | Nil |
TNI Research calculations. Fidson's TTM EPS uses the post-rights 3.0bn shares.
Sector themes for 2026
1. FX calm was the single biggest earnings driver. The official rate held roughly between N1,326 and N1,331 per dollar through September 2026, reserves reached an 18-year high, and September inflation fell to 14.63%. For import-dependent drugmakers, this shrank FX revaluation losses (Fidson's fell from N4.16bn to N104m) and let earlier price increases flow into wider margins (May & Baker's gross margin rose about 10 points). MeCure's gross margin barely moved, which suggests weaker pricing power or savings passed on to customers to win volume.
2. Rates have started to fall, but the debt-heavy names have not benefited yet. The CBN cut the MPR by 350bp to 23% on 22 September 2026, too late for most of 9M 2026. Fidson cut finance costs 27% by repaying commercial paper; MeCure's rose 33% to N8.84bn; May & Baker's subsidised BOI loan was repriced up to 15% from 9% in June. The September cut is the most important Q4 and 2027 swing factor for MeCure and Neimeth.
3. The new tax regime is showing up in effective tax rates. The Nigeria Tax Act 2025 keeps CIT at 30% and adds a 4% Development Levy. Fidson's and May & Baker's effective tax rates of about 34% match that. MeCure's 9M tax charge is exactly 30.0% of PBT, so investors should ask whether the levy has been fully provided for.
4. Working capital is the hidden cost of growth. Fidson's receivables rose about 165% to N29.32bn; May & Baker's inventories doubled to N9.71bn, funded by suppliers; MeCure capitalised N16.7bn of capex in nine months. Stocking up on raw materials while the naira is stable is sensible, but it raises write-down risk.
5. Local manufacturing policy helps, unevenly. The import-duty and VAT exemption on designated pharmaceutical raw materials runs to March 2027. MeCure's customs duty in cost of sales fell from N695.7m to N169.9m, consistent with that waiver.
Ranking and verdict
May & Baker: top pick on quality and value. Margin expansion, net cash, about 23x interest cover, 9.7x P/E. Risks: whether the 44% gross margin can last, and the inventory and payables build-up.
Fidson: quality growth, full price. The best franchise and scale, falling finance costs, Q3 PAT doubling. Risks: receivables and debt rising faster than sales, and about 19x P/E.
MeCure: strong operations, fragile balance sheet. About 2x interest cover, 224% gearing, about 28x P/E and a 13.9% free float. The rate cut and successful refinancing are the upside triggers.
Neimeth: unverified and leveraged. Revenue momentum is real, but interest cover is near 1x and the valuation is around 35x. Wait for verified 9M and FY numbers.
What to watch in Q4 / FY 2026
Whether finance costs at MeCure and Neimeth fall after the rate cut.
Whether Fidson's receivables convert to cash, and whether its borrowings fall.
Whether May & Baker's gross margin holds above 40% as cheap inventory is used up.
Development Levy provisioning in FY audited accounts.
Q4 dividend declarations against cash, not just profit.
Sources
Sources: company 9M 2026 unaudited filings on NGX (Fidson figures via Nairametrics and BusinessDay coverage of its filing). Ratios are TNI Research calculations. This is analysis for education, not investment advice. Do your own research or consult a licensed adviser.